SLNO

Soleno Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality4/10
  • Growth↑ 8/10
  • Value↓ 1/10
Soleno Therapeutics sales and earnings growth
SLNO Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 109.13%
  • FCF Y/Y↑ 167.41%
Soleno Therapeutics gross and profit margin trends
SLNO Profitability
Good
  • Gross margin ↑ 98.60%
  • EPS margin↑ 10.80%
  • ROIC 5Y↓ 63.18%
Soleno Therapeutics net debt vs free cash flow
SLNO Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ 4.8

Soleno Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗